FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness Susvimo is the first and only continuous delivery treatment ...

Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular degeneration (AMD) – SOUTH SAN FRANCISCO, CA, USA I February 04, 2025 I Genentech, a member of ...

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price ...

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment shown to ...